Skip to main content
OpenTrials
Completed

NCT Number: NCT02421887

Males, Antioxidants, and Infertility Trial

The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether treatment of infertile males with an antioxidant formulation improves male fertility. The central hypothesis is that treatment of infertile males with antioxidants will improve sperm structure and function, resulting in higher fertilization rates and improved embryo development, leading to higher pregnancy and live birth rates. Findings from this research will be significant in that they will likely lead to an effective, non-hormonal treatment modality for male infertility. An effective treatment for men would also reduce the treatment burden on the female partner, lower costs, and provide effective alternatives to couples with religious or ethical contraindications to ART (Assisted Reproductive Technology). If antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity, they could allow for couples with male factor infertility to use less intensive therapies such as intrauterine insemination. Male fertility specialists currently prescribe antioxidants based on the limited data supporting their use. A negative finding, lack of any benefit, would also alter current treatment of infertile males.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Keck School of Medicine of University of Southern California, Los Angeles, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Couple

  • 12 or more months of infertility (primary or secondary)
  • Heterosexual
  • Cohabitating and able to have regular intercourse

Male:

  • ≥ 18 years of age
  • At least one abnormal semen parameter on a semen analysis within the past 6 months:
  • Sperm concentration ≤15 Million/ml
  • Total motility ≤40%
  • Normal morphology (Kruger) ≤4%
  • DNA fragmentation (SCSA, DNA fragmentation index) >25%

Female:

  • ≥18 years of age and ≤40 years of age
  • For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL, AMH ≥ 1.0 ng/mL, OR antral follicle count >10 within one year prior to study initiation.
  • Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram or laparoscopy showing at least one patent fallopian tube or a saline infusion sonogram showing spillage of contrast material
  • Regular cycles defined as ≥25 days and ≤35 days in duration
  • Evidence of ovulation including biphasic basal body temperatures, positive ovulation predictor kits, or progesterone level ≥3 ng/ml.

Exclusion criteria

  • Couple:
  • Previous sterilization procedures (vasectomy, tubal ligation). The prior procedure may affect study outcomes.
  • Planning in vitro fertilization in the next 6 months

Male:

  • Sperm concentration < 5 million/mL on screening semen analysis
  • Current use of a medication or drug that would affect reproductive function or metabolism (see Appendix C for list)
  • Current multivitamin or herb use (requires 1 month wash-out)
  • Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
  • Current use of anticoagulants
  • Untreated hypothyroidism
  • Uncontrolled diabetes mellitus

Female:

  • History of surgically or medically confirmed moderate or severe endometriosis
  • Body mass index >35 kg/m2
  • Currently pregnant
  • History of polycystic ovarian syndrome
  • Current serious medical illnesses, such as cancer, heart disease, or cirrhosis
  • History of systemic chemotherapy or pelvic radiation
  • Current use of a medication or drug that would affect reproductive function or metabolism

Treatment and study plan

Antioxidant Supplement

Drug

An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine

Placebo

Other

Placebo

Primary outcomes

  1. Live Birth Rate

    Time frame: up to 15 months

Secondary outcomes

  1. Pregnancy Rate

    Time frame: up to 7 months

  2. Miscarriage Rate

    Time frame: up to 9 months

    miscarriages per total number of pregnancies

  3. Time to Pregnancy

    Time frame: up to 7 months

    Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as a human Chorionic Gonadotropin (hCG) value over 5 on 2 separate occasions.

  4. Change in Total Motile Sperm Count

    Time frame: baseline and 3 months

    Samples will be assessed using a standard semen analysis

  5. Change in Deoxyribonucleic Acid (DNA) Fragmentation Index (DFI)

    Time frame: Baseline and 3 months

    DFI is the ratio of damaged sperm to total sperm. It is measured using Sperm Chromatin Structure Analysis (SCSA) which was performed on 5000 sperm per sample.

  6. Change in Semen Total Motility

    Time frame: baseline and 3 months

    Samples assessed using a standard semen analysis

  7. Change in Sperm Concentration

    Time frame: baseline and 3 months

    Samples assessed using a standard semen analysis

  8. Change in Normal Morphology of Semen, Using World Health Organization (WHO) 5 Criteria

    Time frame: baseline and 3 months

    Samples assessed using a standard semen analysis

  9. Change in Total Sperm Count

    Time frame: baseline and 3 months

    Samples assessed using a standard semen analysis

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Augusta University
  • Penn State University
  • University of California, San Francisco
  • University of North Carolina
  • University of Oklahoma
  • University of Pennsylvania

Registry information

Official study title

Males, Antioxidants, and Infertility (MOXI) Trial

Acronym: MOXI

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Apr 21, 2015
Registry last updated
Sep 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.